EDIT News and Press, Editas Medicine Inc. From 04/02/24

2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...

2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...

2024-03-13 19:58:04 ET Editas Medicine, Inc. (EDIT) Barclays 26th Annual Global Healthcare Conference March 13, 2024 02:05 PM ET Company Participants Gilmore O'Neil - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants ...

2024-03-12 15:56:10 ET Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference March 12, 2024, 10:40 AM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - Conference Call Participants Mani Foroohar - Leerink Presentation ...

2024-03-07 03:31:00 ET With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (NASDAQ: EDIT) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming o...

2024-03-06 17:05:03 ET Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference March 04, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phil Nadeau - TD Cowen Presentation ...

2024-03-04 10:30:00 ET Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (NASDAQ: EDIT) , a...

2024-03-02 21:49:55 ET Shares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence . By the time the market closed on Friday, the stock was still up 34.8%. The catalyst that va...

Editas Medicine, Inc. (NASDAQ: EDIT) is one of today's top gainers. The company's shares have moved 27.99% on the day to $11.34. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It devel...

Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY t...